Literature DB >> 33119876

NK Cells in the Tumor Microenvironment.

Camille Guillerey1.   

Abstract

Natural killer cells are powerful effectors of innate immunity that constitute a first line of defense against cancer. NK cells express an array of germline-encoded receptors which allow them to eliminate transformed cells and spare normal, healthy cells. Owing to their ability to kill circulating tumor cells, NK cells play a major role in the protection against cancer metastases. There is also convincing evidence that NK cells protect against some hematological cancers such as acute myeloid leukemia. However, the importance of NK cells for the control of established solid tumors is rather uncertain. Several mechanisms impede NK cell-mediated elimination of solid tumors, starting with the incapacity of NK cells to infiltrate the core of the tumor. In addition, immune escape mechanisms are at play in both solid and hematological cancers. These include the immunoediting of tumor cells and aberrant chronic inflammation that renders NK cells ineffective. In this chapter, I review the phenotypic characteristics of NK cells within the tumor microenvironment. Furthermore, I describe the mechanisms by which NK cells contribute to antitumor immunity. Finally, I review the different immune-evasion factors that impair NK cell activity against cancer.

Entities:  

Keywords:  Cancer immunology; Cytokines; Dendritic cells; ILCs; Immune checkpoints; Immune escape; Immunoediting; Immunosurveillance; Immunotherapy; Innate immunity; Leukemia; Metastases; NK cell receptors; Natural killer cells; T cells

Mesh:

Year:  2020        PMID: 33119876     DOI: 10.1007/978-3-030-49270-0_4

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  9 in total

1.  Inability of ovarian cancers to upregulate their MHC-class I surface expression marks their aggressiveness and increased susceptibility to NK cell-mediated cytotoxicity.

Authors:  Nishant Chovatiya; Kawaljit Kaur; Sara Huerta-Yepez; Po-Chun Chen; Adam Neal; Gabriella DiBernardo; Serhat Gumrukcu; Sanaz Memarzadeh; Anahid Jewett
Journal:  Cancer Immunol Immunother       Date:  2022-05-04       Impact factor: 6.630

2.  A 16-gene signature associated with homologous recombination deficiency for prognosis prediction in patients with triple-negative breast cancer.

Authors:  Daodu Wang; Yifeng Shi; Hanyang Huang; Qijiong Zhao; Yongyue He; Wenzhi Su
Journal:  Open Med (Wars)       Date:  2022-05-11

Review 3.  The Immune Landscape of Human Pancreatic Ductal Carcinoma: Key Players, Clinical Implications, and Challenges.

Authors:  Marie Muller; Vincent Haghnejad; Marion Schaefer; Guillaume Gauchotte; Bénédicte Caron; Laurent Peyrin-Biroulet; Jean-Pierre Bronowicki; Cindy Neuzillet; Anthony Lopez
Journal:  Cancers (Basel)       Date:  2022-02-16       Impact factor: 6.639

4.  Identification of Paxillin as a Prognostic Factor for Glioblastoma via Integrated Bioinformatics Analysis.

Authors:  Zhehao Huang; Hailiang Wang; Dongjie Sun; Jun Liu
Journal:  Biomed Res Int       Date:  2022-06-23       Impact factor: 3.246

Review 5.  CAR-NK Cells: A Chimeric Hope or a Promising Therapy?

Authors:  Mohamad Sabbah; Ludovic Jondreville; Claire Lacan; Francoise Norol; Vincent Vieillard; Damien Roos-Weil; Stéphanie Nguyen
Journal:  Cancers (Basel)       Date:  2022-08-08       Impact factor: 6.575

Review 6.  The role of tumor-associated macrophages in oral squamous cell carcinoma.

Authors:  Yiwen Xue; Xiao Song; Siyu Fan; Runzhi Deng
Journal:  Front Physiol       Date:  2022-08-29       Impact factor: 4.755

Review 7.  Underlying mechanisms of evasion from NK cells as rationale for improvement of NK cell-based immunotherapies.

Authors:  Barbara Seliger; Ulrike Koehl
Journal:  Front Immunol       Date:  2022-08-12       Impact factor: 8.786

Review 8.  Tumor microenvironment: barrier or opportunity towards effective cancer therapy.

Authors:  Aadhya Tiwari; Rakesh Trivedi; Shiaw-Yih Lin
Journal:  J Biomed Sci       Date:  2022-10-17       Impact factor: 12.771

9.  Immunonutrition Changes Inflammatory Response in Colorectal Cancer: Results from a Pilot Randomized Clinical Trial.

Authors:  Mateusz Wierdak; Marcin Surmiak; Katarzyna Milian-Ciesielska; Mateusz Rubinkiewicz; Anna Rzepa; Michał Wysocki; Piotr Major; Stanisław Kłęk; Michał Pędziwiatr
Journal:  Cancers (Basel)       Date:  2021-03-22       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.